Where our drug guidance comes from

Every pharmacogenetic recommendation in a Gene2Rx report is traceable to a published source. These are the organizations behind that guidance, and every drug each one covers.

A pharmacogenetic guideline links a gene result to a prescribing action. Different bodies produce these on different terms: some are clinical protocols, some are regulatory labeling. Gene2Rx draws on all of them so a report reflects the full weight of the evidence.

FDA

U.S. Food and Drug Administration

Government regulatory agency

FDA guidance is regulatory rather than a clinical protocol. A label may note that a genetic subgroup has altered drug levels, carries a higher risk of a side …

65 drugs CPIC

Clinical Pharmacogenetics Implementation Consortium

International expert consortium

CPIC does not decide whether a gene should be tested. It answers the next question: given that a result is already available, how should the prescription change? For …

56 drugs Gene2Rx

Gene2Rx curated guidance

Internally curated set

Gene2Rx-curated guidance is intended to fill gaps, not to replace the established bodies. Where CPIC, the FDA, or the DPWG later publish on the same drug, that source …

10 drugs DPWG

Dutch Pharmacogenetics Working Group

National expert working group

Gene2Rx includes a curated set of DPWG recommendations where they add clinically meaningful guidance beyond CPIC and the FDA, currently covering haloperidol, quetiapine, allopurinol, and zuclopenthixol. For each …

4 drugs

Informational only, not medical advice. The presence of a pharmacogenetic guideline does not mean every patient needs to change their dose. Never start, stop, or change a medication without talking to your prescribing clinician.